AB Science is a clinical-stage pharmaceutical company developing innovative drugs targeting diseases with unmet medical needs.
Our two main compounds are developed in the field of oncology, inflammatory diseases and neurological degenerative disorders. Masitinib, AB Science main product, is well advanced clinically with positive phase 3 data in Amyotrophic Lateral Sclerosis (ALS), indolent severe systemic mastocytosis, severe asthma and progressive forms of multiple sclerosis.